We also evaluated the utility of a VEGF pathway inhibitor (sorafenib), a HMG-CoA reductase inhibitor (atorvastatin), and an MMP inhibitor (doxycycline) using the subcutaneous Tsc2-/- tumor model. This evidence concerns the gene VEGFA and neoplasm.